Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

940 - The correlation between toll-like receptor genes polymorphisms, tumor microenvironment characteristics and the effectiveness of preoperative chemotherapy for locally advanced breast cancer


11 Sep 2017


Poster display session


Translational Research;  Breast Cancer


Nataliia Verovkina


Annals of Oncology (2017) 28 (suppl_5): v68-v73. 10.1093/annonc/mdx364


N. Verovkina1, L.A. Sivak1, S. Lyalkin1, Z.I. Rossokcha2, P.E. Fedorovna2

Author affiliations

  • 1 Department Of The Chemotherapy Of The Solid Tumors, National cancer institue, 3022 - Kiev/UA
  • 2 Reference Center Of Molecular Diagnostics Of The Ministry Of Health Of Ukraine “, Reference center of molecular diagnostics of the Ministry of health of Ukraine “, 04112 - Kiev/UA


Abstract 940


Toll-like receptor (TLR) activation may be an important event in tumor cell immune evasion. TLR2 and TLR4 gene polymorphisms correlate with increased susceptibility to cancer development, response to conventional chemotherapy in various organs.


Treatment results of 62 patients with breast cancer stages T1-3N0-3M0 treated with neoadjuvant chemotherapy were evaluated. The level of the post-treatment CD4+, CD8+, FOP3+ tumor-infiltrating immune cells and Ki-67 positive cells were studied. The polymorphisms of TLR4 (C399T) and TLR2 (G753A) genes were investigated using a PCR restriction fragment length polymorphism method. Statistica10.0 software was used to perform analysis of variance.


ER+ and PR± expressing tumors were identified in 69.3% of patients, ER and PR negative tumors - in 30.6%. Pathological complete response (pCR) was identified in 14.6%. Genotype CC of TLR4 (C399T) gene was detected in 87%, whereas genotype CT - in 9.6% and genotype TT - in 3.4% of patients. Genotype GG of TLR2 (G753A) gene was detected in 88.7%, genotype GA - in 11.3% of patients. A correlation was found between polymorphisms of TLR2 (G753A) and axillary lymph nodes involvement. In carriers of GA genotype of TLR2 gene (G753A) we found more frequent axillary LN metastases (χ2=5.75; p = 0.01). A direct correlation was identified between level of Ki-67 and the level of regulatory FOXP3 cells in carriers of GA genotype of TLR2 gene(r = 0.96; p = 0.008). There appears to be a relationship between TLR4 gene and levels of CD4 + (p=0.01) and CD8 + (p=0.02) as well as an association between TLR4 (C399T) gene and residual cancer burden (RCB) (p = 0.04). In carriers of TT genotype of TLR4 gene the level of CD4+ cells was significantly lower (p = 0.03). In carriers of CC genotype of TLR4 (C399T) gene we found a direct correlation between the level of CD8+ cells and Ki- 67 in the residual tumor (r = 0.38, p = 0.01). Higher level of CD4+ is associated with lower RCB in carriers of CC genotype of TLR4 (C399T) gene (r = 0.3, p 


Preliminary results of the study indicate that further elucidation of the role of the TLRs in breast cancer development is promising.

Clinical trial identification

Legal entity responsible for the study

National Cancer Institute


National cancer institute


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.